Objective: To determine the feasibility and effectiveness of androgen treatment of depressive symptoms in older men.
F or 3 reasons, depressive disorders in the elderly are becoming one of the most frequent clinical situations challenging health care professionals. First, people aged 65 years and over represent the fastest-growing population in Canada. Their numbers rose by almost 60% between 1981 and 1998, reaching a total of 3.7 million (for Health Canada 2003 statistics, see www.hc-sc.gc.ca/seniors-aines). Second, the prevalence rate of major depression in the elderly ranges from 1% to 4% in the community (1) ; the rate rises to 10% to 30% in elderly medical inpatients (2) . Third, major depression in many elderly individuals is a chronic disorder characterized by recovery and recurrence. A recent study confirmed that elderly subjects suffer from more rapid recurrence than younger patients, with a median time to recurrence of 90 weeks in the group aged 65 to 79 years (3).
Moreover, older patients seem to suffer much more frequently from minor or subthreshold depression than from major depression. Among those aged 55 years and over in a community sample, the prevalence rate was 12.9% (1) . Among older men, subthreshold depression is associated with as much disability as MDD and with an increased risk of death, compared with control subjects not suffering from depression (4,5). Beekman and others followed a group of 277 elderly subjects with depression for 6 years (average age at the beginning of the study, 71.8 years) (1) . The most frequent diagnosis was subthreshold depression (75%, compared with 8% having MDD); 66% of these patients had a chronic-intermittent or chronic course of disease over the 6 years.
The prevalence rate of low levels of total testosterone in men aged over 60 years is reported to be approximately 20% (6, 7) . Low levels of testosterone are associated with depressive symptoms that include lack of energy, an irritable or sad mood, and decreased enjoyment of life, as determined by the St-Louis Testosterone Deficiency Questionnaire (8) . Patients can also report a decreased sense of well-being, fatigue, decreased libido, and erectile dysfunction (7).
Shores and others examined the link between diminished testosterone levels and the incidence of depressive illness in a historical cohort study (9) . They concluded that a total testosterone level of 200 ng/dL or less increased the risk of depression approximately fourfold in older men (that is, those aged 45 years and over). Seidman and others found that most of the elderly men with dysthymic disorder in their study had total testosterone levels in the hypogonadal range (mean 295 mg/dL)-levels significantly lower than the mean levels obtained in their groups with and without depression (10) .
The high frequency of depressive symptoms and low testosterone levels in older men has made testosterone an appealing treatment for depression in this population. As early as the 1940s, testosterone was used as a treatment for depression (11, 12) . In recent years, there has been a growing literature on "andropause" and an increase in avertisements for testosterone medications. For example, the May 2003 issue of Doctors Review (see www.doctorsreview.com/index.html) contained advertisements for 3 different formulations of testosterone. Similarly, at the 2003 congress of Psychiatry in Hull, Quebec (« Sexe et Psyché », 37ième congrès annuel de l'AMPQ), 3 different specialties-urology, endocrinology, and psychiatry-presented on this topic. Thus the objective of our systematic review was to determine the evidence for the feasibility and effectiveness of androgen treatment of depressive symptomatology in older men. The review process, modified from that suggested by Oxman and others (13) , involved systematic selection of articles, review of the quality of each study, abstraction of data, and qualitative synthesis of results.
Methods

Article Selection
One author used 3 different strategies to identify all potentially relevant articles. First , and the Cochrane Database of Systematic Reviews), but we found no additional articles. Second, potentially relevant articles were retrieved and the bibliographies screened for additional references. Finally, one author contacted specialists who had written or lectured on this subject (2 psychiatrists and an endocrinologist), as well as apposite pharmaceutical companies, to identify any relevant new, ongoing, or unpublished studies.
All potentially relevant articles were screened independently by both authors to meet the following 4 inclusion criteria: original investigation, published in English or French, use of acknowledged criteria for depression and dysthymia and (or) an accepted scale to measure depressive symptoms, and open or randomized trial of treatment with androgen therapy. 
Assessment of Validity
Four elements concerning the quality of the studies (as described by Jadad and others, 14) were abstracted independently by both authors. These criteria were randomization, double blinding, comparability of treatment and control groups at baseline, and description of dropouts.
Data Synthesis
One author abstracted and tabulated the following information from each article: study design and duration; population from which the patients were selected; patient age, sex, and gonadal status; inclusion and exclusion criteria; number of patients enrolled and completing the study; description of treatment and control groups; frequency of secondary effects requiring withdrawal from treatment; assessment and diagnostic tools; and results. To determine feasibility, we tabulated for each study the frequency of withdrawal due to proven or potential secondary effects. To determine effectiveness, we compared measures before and after treatment in the case of open trials. In the case of randomized trials, we compared the measures between treatment groups or treatment and control groups. The studies used different depression rating scales, and sometimes multiple scales, but at least one scale (usually the HDRS) was the accepted measure of depressive symptoms. When 2 or more acceptable scales were used, we reported the results of the HDRS only; if there were conflicting results with different scales, we reported all the results.
Results
Article Selection
We retrieved 25 potentially relevant articles, of which 17 met the inclusion criteria (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . The interrater agreement for this phase of the study was 97%; consensus was obtained through discussion between the authors. The review includes 8 open trials and 12 RCTs because 3 articles (15, 19, 21) reported studies of 2 designs (see Note).
Assessment of Validity
Interrater agreement between the authors on the 4 criteria of methodological quality was 89%; consensus was achieved through discussion between the authors. Most of the randomized trials had one or more methodological limitations.
Data Synthesis
Studies and Populations. The studies included 856 patients. Patients were generally male , although female subjects were enrolled in 3 studies (17, 25, 26 (16, (18) (19) (20) (21) (22) (27) (28) (29) (30) (31) , and 3 used DHEA (17, 25, 26) . Study duration was short, (3 to 14 weeks), except for 2 studies of 5 and 6 months' duration, respectively (18, 27) .
Feasibility. With regard to feasibility, 73% to 100% of subjects completed the studies in which they were enrolled. Only 5 studies reported withdrawals related to secondary effects (16, 19, 26, 30, 31) . In most studies, the secondary effects were not specified. (30) . Of the 3 best-quality studies, 2 had negative results (29, 31) , and 1 was equivocal (30) . In 3 of the 5 positive studies (25, 28, 30 ) the testosterone preparation was combined with antidepressant medication. Testosterone status at baseline did not appear to be related to the results of either the open or randomized trials. We were unable to do a quantitative metaanalysis of the results of the randomized trials because different androgen preparations were used and only 5 of the 12 reports offered sufficient information to calculate effect sizes.
Effectiveness
Discussion
We proposed to determine the feasibility and effectiveness of androgen treatment for depressive symptomatology in older men. Although we located 8 open trials and 12 randomized trials, only 2 open trials enrolled subjects whose mean ages were greater than 60 years. The results of one were positive, and the results of the other were negative. The results of the remaining 18 trials suggest that androgen therapy is feasible in younger men in the short term (that is, 3 to 14 weeks), but even in this younger population, there is little evidence that androgen therapy alone is an effective treatment for depressive symptoms.
This review highlights the variability of the different studies in this field of research. To start with, the treatments did not In the studies that used mesterolone, patients were not exposed to estradiol, which could explain in part the negative results obtained. Other studies used the adrenal androgen DHEA, which is converted into testosterone and estrogens.
Also, different types of testosterone preparations were used: gel in 2 studies and intramuscular preparations in 11 studies. Dosages (amount and frequency of doses) were quite different, ranging from DHEA 30 to 450 mg daily, mesterolone 50 to 450 mg daily, testosterone gel 5 to 10 g daily, and testosterone injection 100 mg once weekly to 400 mg biweekly. Interestingly, in 2 studies using transdermal testosterone (20, 30) , the authors reported that fewer than 50% of the hypogonadal patients had a doubling of their plasma-free testosterone level and that 3 of the 11 testosterone subjects had increases of 70 ng/dL or less in their total testosterone levels. This variability makes it difficult to conclude which specific treatment is useful.
The populations were heterogeneous: healthy eugonadal volunteers in some studies and HIV-positive patients with wasting or older patients with Parkinson's disease in others. According to available data (mean age was not always given), the patients' mean age was about 40 years in most studies. This limits the generalizability of positive results to older patients. Notably, advertising by pharmaceutical companies targets men suffering from andropause, even if evidence of efficacy in this age group, at least concerning mood symptoms, is limited because few older subjects have been studied.
In Grinspoon and others' study, 35% of the testosterone effect on mood could be explained by increased weight (multivariate analysis), possibly indicating an indirect effect of testosterone (27) . Possibly, depressive symptoms and low testosterone levels are markers of the same disease state in some patients, with no causal relation between them.
In another study, the results were negative for hypogonadal patients suffering from MDD (29) . These patients were not allowed concomitant psychotropic medication during the blinded phase. In an open trial by the same authors, patients had a positive response to testosterone treatment used as an adjunct to treatment with selective serotonin reuptake inhibitors (18) . These results suggest that testosterone treatment might be useful in hypogonadal patients with depressive symptoms, probably more as an adjunctive treatment than as a first-line treatment. In Rabkin and others' study, results in subgroups of patients were examined to determine whether patients with MDD were more likely to respond to testosterone injections (400 mg biweekly) than were subjects with only subthreshold symptoms (31). The conclusion was negative.
The study durations were noticeably short, usually 6 to 8 weeks. This might result in negative findings if it takes more time for significant changes in symptoms to occur. However, patients who responded positively seemed to do so rapidly. Seidman and others reported a significant decrease in HDRS scores as early as Week 2 (18) There has been concern about the safety of androgen treatment. In the short term, it appears that patients tolerate the treatment well and that there are few adverse effects. However, serious consequences of long-term exposure to androgen therapy have been documented, including heart failure, peripheral edema, acne, prostate disorders, gynecomastia, hypercalcemia, sleep apnea, and laboratory test abnormalities, (elevated gamma-glutamyltransferase, total bilirubine, hematocrit, and hyperlipidemia; decreased high-density lipoprotein; and hypokalemia) (32, 33) .
This review has 3 limitations. First, we limited our literature search to French and English articles. Second, we did not assess the reliability of the literature search or data abstraction. Third, we were unable to do a quantitative metaanalysis.
To conclude, androgen therapy may be feasible in the short term, but there is little evidence that it is an effective treatment of depressive symptoms in older men
Note
Tables showing details of the studies reviewed for this paper are available in the online version of the article at www.cpa-apc.org/Publications/cjpHome.asp.
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Résumé : Le traitement à l'androgène des symptômes dépressifs chez les hommes âgés : une étude systématique de la faisabilité et de l'efficacité Objectif : Déterminer la faisabilité et l'efficacité du traitement à l'androgène des symptômes dépressifs chez les hommes âgés.
Méthode : Nous avons cherché des articles pertinents dans MEDLINE, PsycINFO, Eric, HealthStar et la base de données Cochrane d'études systématiques. Les bibliographies des articles relevés ont été recherchées en vue de références additionnelles, et des experts ont été consultés. Dix-sept études (8 essais ouverts et 12 randomisés; 3 articles rapportaient des études des 2 méthodes) satisfaisaient aux critères d'inclusion suivants : recherche originale; publiée en anglais ou en français; utilisation des échelles ou des critères reconnus de la dépression; et essai ouvert ou randomisé du traitement à l'androgène. Quatre critères évaluaient la validité des études : randomisation, double insu, comparabilité du groupe de traitement et du groupe témoin au départ, et description des abandons. L'information a été extraite de chaque article, totalisée et comparée.
Résultats :
La plupart des études avaient des limitations méthodologiques. En ce qui concerne la faisabilité, il y avait peu de retraits déclarés en raison d'effets indésirables. Pour ce qui est de l'efficacité, 6 sur 8 des essais ouverts ont eu des résultats positifs, et 5 sur 12 des essais randomisés ont aussi eu des résultats positifs. Cependant, la testostérone a été combinée avec un antidépresseur dans 3 de ces essais randomisés positifs. Seulement 2 essais ouverts ont inscrit des sujets dont l'âge moyen était de 60 ans et plus. L'un a eu des résultats positifs, et l'autre, des résultats négatifs.
Conclusion :
Le traitement à l'androgène peut être faisable à court terme, mais il y a peu de données probantes que le traitement est efficace pour les symptômes dépressifs chez les hommes âgés.
